REDWOOD CITY, Calif., April 11, 2008 (PRIME NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced multiple presentations regarding its oncology pipeline, which includes three preclinical presentations on its hypoxia-activated prodrugs. TH-302, the lead hypoxia-activated prodrug, began a Phase 1 clinical trial in July 2007 and plans to enter Phase 1 and 2 studies with docetaxel, gemcitabine, and pemetrexed in the third quarter of 2008. The presentations will take place at the 2008 American Association for Cancer Research (AACR) annual meeting being held April 12 - 16, 2008, at the San Diego Convention Center in San Diego, CA.
The following presentations will take place on Sunday, April 13 from 1:00pm to 5:00pm:
Poster 1441: In vitro activity profile of the novel hypoxia-activated cytotoxic prodrug TH-302;
Poster 1442: Anti-cancer activity of TH-1011, a novel hypoxia-activated prodrug, is related to tumor vessel disruption; and
Poster 1447: Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the hypoxically activated prodrug, TH-302, in mice, rats, dogs and monkeys.
The following presentation will take place on Monday, April 14 from 1:00pm to 5:00pm:
Poster 2714: The antiproliferative activity of 3-Bromopyruvate is not due to selective inhibition of glycolysis.
Copies of the posters may be obtained by calling the Company.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com).
Forward-Looking Statements
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, and potential therapeutic uses and benefits of our product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to commence its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Annual Report on Form 10-K, which was filed with the Securities Exchange Commission on March 12, 2008 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.